Product
VRC07-523LS
Aliases
VRC-HIVMAB075-00-AB
11 clinical trials
13 indications
Indication
HIV-1 infectionIndication
HIV InfectionIndication
HIV InfectionsIndication
HIVIndication
Acquired Immunodeficiency SyndromeIndication
Immunodeficiency SyndromeIndication
AcquiredIndication
Sexually Transmitted InfectionsIndication
ViralIndication
Retroviridae InfectionsIndication
Acute HIV InfectionIndication
PLWHIndication
Antiretroviral TherapyClinical trial
Safety and Efficacy of Broadly Neutralizing Antibodies Followed by Innate Immune Stimulation and Therapeutic Vaccination for the Induction of HIV RemissionStatus: Withdrawn, Estimated PCD: 2025-07-01
Clinical trial
Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure ProphylaxisStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment InterruptionStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Phase 1 Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult ParticipantsStatus: Completed, Estimated PCD: 2023-07-19
Clinical trial
A Safety, Immunogenicity and Efficacy Phase 1/2a Study of a Heterologous Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Regimen Plus Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults on Suppressive ARTStatus: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Multicenter, Randomized, Partially Blinded Phase 1 Clinical Trial to Evaluate the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected AdultsStatus: Completed, Estimated PCD: 2020-12-07
Clinical trial
Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed InfantsStatus: Completed, Estimated PCD: 2020-06-17
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV RemissionStatus: Not yet recruiting, Estimated PCD: 2025-09-06
Clinical trial
A Phase 1 Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsStatus: Completed, Estimated PCD: 2023-01-18
Clinical trial
A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living With HIV-1Status: Completed, Estimated PCD: 2024-04-29
Clinical trial
Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV): Safety and Efficacy of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination for the Induction of HIV RemissionStatus: Not yet recruiting, Estimated PCD: 2027-08-01